Biohaven Ltd. (BHVN)
15.30
+0.82
(+5.66%)
USD |
NYSE |
Nov 09, 12:07
Biohaven Enterprise Value : 2.326B for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 2.326B |
| November 05, 2026 | 2.238B |
| November 04, 2026 | 2.441B |
| November 03, 2026 | 2.497B |
| November 02, 2026 | 2.429B |
| October 30, 2026 | 2.468B |
| October 29, 2026 | 2.629B |
| October 28, 2026 | 2.483B |
| October 27, 2026 | 2.448B |
| October 26, 2026 | 2.321B |
| October 23, 2026 | 2.235B |
| October 22, 2026 | 2.358B |
| October 21, 2026 | 1.913B |
| October 20, 2026 | 1.923B |
| October 19, 2026 | 1.853B |
| October 16, 2026 | 1.767B |
| October 15, 2026 | 1.865B |
| October 14, 2026 | 1.790B |
| October 13, 2026 | 1.864B |
| October 12, 2026 | 1.923B |
| October 09, 2026 | 1.963B |
| October 08, 2026 | 1.941B |
| October 07, 2026 | 1.933B |
| October 06, 2026 | 1.963B |
| October 05, 2026 | 2.098B |
| Date | Value |
|---|---|
| October 02, 2026 | 2.083B |
| October 01, 2026 | 2.123B |
| September 30, 2026 | 2.155B |
| September 29, 2026 | 2.036B |
| September 28, 2026 | 2.033B |
| September 25, 2026 | 1.991B |
| September 24, 2026 | 2.021B |
| September 23, 2026 | 2.093B |
| September 22, 2026 | 2.272B |
| September 21, 2026 | 2.177B |
| September 18, 2026 | 2.086B |
| September 17, 2026 | 2.127B |
| September 16, 2026 | 1.844B |
| September 15, 2026 | 1.893B |
| September 14, 2026 | 1.938B |
| September 11, 2026 | 1.948B |
| September 10, 2026 | 1.961B |
| September 09, 2026 | 2.294B |
| September 08, 2026 | 2.252B |
| September 04, 2026 | 2.399B |
| September 03, 2026 | 2.424B |
| September 02, 2026 | 2.399B |
| September 01, 2026 | 2.406B |
| August 31, 2026 | 2.335B |
| August 28, 2026 | 2.356B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.067M |
| Brainstorm Cell Therapeutics, Inc. | 11.28M |
| Summit Therapeutics, Inc. | 12.45B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 13.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -129.28M |
| Total Expenses (Quarterly) | 129.28M |
| EPS Diluted (Quarterly) | -0.8559 |
| Earnings Yield | -25.25% |
| Normalized Earnings Yield | -24.63 |